|
||
|
|
|
|
Speaker Biographies Adrian BirdFollowing his PhD at Edinburgh University in 1970, Dr Bird undertook postdoctoral research at the Universities of Yale and Zürich. In 1975 he returned to the MRC Mammalian Genome Unit in Edinburgh, where his research focused on DNA methylation and the existence of CpG islands as markers for mammalian genes. Following 3 years at the Institute for Molecular Pathology in Vienna, he moved back to Edinburgh as Buchanan Professor of Genetics in 1990. During this period he established a mechanistic connection between DNA methylation and chromatin via methyl-CpG binding proteins. His laboratory discovered the first such protein, MeCP2 and generated a mouse model for Rett Syndrome. Since 1995 Dr Bird has been Director of the Wellcome Trust Centre for Cell Biology. Marie-Andrée AkimenkoFollowing her PhD at the Institut Pasteur in Paris, Marie-Andrée
Akimenko did her postdoctoral training at the University of Oregon, where
she developed an interest in using the zebrafish as an animal model to
study embryonic development and fin regeneration. In 1992, she joined
the Ottawa Health Research Institute (OHRI) affiliated to the University
of Ottawa where she is currently Senior Scientist at the OHRI and Professor
in the Departments of Medicine and of Cellular and Molecular Medicine.
She is one of the pioneers in the molecular analysis of the mechanisms
of fin regeneration in zebrafish. Her research focus in the last few years
has been aimed at understanding the role of the hedgehog and bone morphogenetic
protein signaling pathways in the overall growth of the regenerate and
in dermal bone patterning during fin development and regeneration. Recent
work has compared the molecular mechanisms of development in dermal bone
with those of endochondral bone. She serves as a member of the editorial
board of the journal “Developmental Dynamics” since 2003.
Dennis BlackDennis Black completed his undergraduate work and received his MA and PhD in biostatistics from the University of California, Berkeley. He subsequently joined the faculty of the University of California, San Francisco, where he is currently Professor in the Department of Epidemiology and Biostatistics. Dr Black is active in both teaching and research, with a focus on osteoporosis and clinical trials. He was the lead investigator on the Fracture Intervention Trial (FIT) of alendronate and is currently Principal Investigator for the Long-term Extension of FIT (FLEX), the PTH and Alendronate (PATH) study, the PTH Once Weekly Research (POWR) and the HORIZON PFT trial of IV zoledronic acid. Dr Black has served on the Council of the American Society for Bone and Mineral Research and serves on many professional/governmental committees, including the National Osteoporosis Foundation Committee on Simplification of BMD Reporting and the World Health Organization Task Force for Osteoporosis. He has been an invited speaker at numerous national and international professional meetings and has published extensively in peer-reviewed journals. He is also the author of several book chapters, and currently serves as a reviewer for a number of professional publications, including the New England Journal of Medicine, JAMA and Journal of Bone and Mineral Research. BollerslevJens Bollerslev is head of Section of Endocrinology at Rikshospitalet in Oslo, Norway and Professor in Endocrinology at the University of Oslo. His scientific interests have primarily been related to monogenetic disorders of bone metabolism (he defended his thesis on human osteopetrosis in 1990) and bone as target tissues for endocrine disorders. For many years he has also been interested in treatment of borderline hypercalcemia due to primary hyperparathyroidism, and took the initiative in a randomized Scandinavian study on the effect of operation versus conservative observation. The first results from this study have recently been published. From the perspective of different mammalian mutations of osteopetrosis, Jens Bollerslev has contributed to international collaborations on the topic of osteoclast dysfunction and the coupling principle. In the bone field, he is currently involved in clinical investigations on bone loss in relation to solid organ transplantation. Lynda F. BonewaldDr Lynda F. Bonewald a Curators’ Professor and the
Lee M. and William Lefkowitz Professor in the Department of Oral
Biology and directs the Bone Biology Research Program at UMKC. Dr Bonewald
has worked in the area of transforming growth factor beta and in the lipoxygenases
but is probably best known for her research in osteocyte biology. Osteocytes
are the most abundant cell in bone and appear to be responsible for sensing
mechanical stress and signaling bone modeling and remodeling. She is Director
of a program project entitled “The Effects of Mechanical Strain
on Osteocyte Function”. The program involves investigators at UMKC,
KUMC, and UTHSC in San Antonio, Texas. Dr Bonewald is presently the Chair
of the Advocacy Committee for American Society for Bone Mineral Research.
She previously chaired the Board of Scientific Counselors of the NIH’s
National Institute of Dental and Craniofacial Research and is Past President
of the Association for Biomolecular Resource Facilities. She
serves on the editorial boards for the Journal for Biomolecular Techniques
and now the Journal for Bone and Mineral Research and is Associate
Editor for Experimental Biology and Medicine. Roberto CivitelliRoberto Civitelli, MD, completed his medical studies and residency in internal medicine at Siena University School of Medicine, Italy, before moving to the Division of Bone and Mineral Diseases at Washington University, in St. Louis, Missouri, where he completed a fellowship in Endocrinology and Metabolism and was appointed full faculty in 1990. He has risen through the ranks to the current position of Professor of Medicine, Orthopaedic Surgery, and Cell Biology and Physiology. His areas of clinical specialty include osteoporosis and bone and mineral diseases. His research interests include cell-cell communication and signaling in bone and regulation of osteoblast differentiation and function. Dr Civitelli is the author of over 100 peer-reviewed manuscripts and invited publications and 13 book chapters. He has served on the editorial boards of the Journal of Clinical Endocrinology and Metabolism, the Journal of Bone and Mineral Research, and the Journal of Laboratory and Clinical Medicine, and he is the editor of Calcified Tissue International. He is a member of several professional organizations including the American Association of Physicians, the American Society for Bone and Mineral Research and the International Bone and Mineral Society. He has received several industry sponsored and federally funded grants from the National Institutes of Health, and the National Aeronautics and Space Administration. Cyrus CooperCyrus Cooper is Professor of Rheumatology and Director of the MRC Epidemiology Resource Centre at the University of Southampton Medical School and Southampton General Hospital in the UK. Professor Cooper graduated from the University of Cambridge and St Bartholomew’s Hospital, London in 1980, and completed his residency in 1985 at the Southampton University Hospitals. He then worked in the MRC Environmental Epidemiology Unit as an MRC Training Fellow, and at the University of Bristol as a Senior Registrar in Rheumatology. In 1990, he won an MRC Travelling Fellowship to the Mayo Clinic, USA, where he continued his research in osteoporosis. Cyrus Cooper returned to the UK in 1992 to take up a position as Senior Lecturer in Rheumatology and MRC Senior Clinical Scientist. He was promoted to the foundation Chair in Rheumatology at the University of Southampton in 1997 while continuing as an MRC Senior Clinical Scientist at the MRC Environmental Epidemiology Unit. In 2003, he was appointed Director of the MRC Epidemiology Resource Centre, University of Southampton. John CunninghamJohn Cunningham is currently Professor of Nephrology at University College London Hospitals, The Royal Free Hospital and University College London, London, UK. Earlier he had been Professor of Renal and Metabolic Medicine and Consultant Physician at St Bartholomew’s and The Royal London School of Medicine & Dentistry where he also served as Admissions Sub Dean and as a Special Trustee for many years. His training was in Cambridge (pre-clinical) and Oxford (clinical) and subsequently in London and at Washington University School of Medicune, St Louis, USA. He has remained an active clinician in nephrology and in general internal medicine. He is a teacher and mentor of clinicians and scientists from undergraduate to senior faculty levels. He runs a research programme examining the following: control by structurally modified vitamin D metabolites of PTH synthesis and release; the synthesis and release of bone cytokines by osteoblast like cells and the regulation of these by vitamin D metabolites; the location and relevance of the extracellular calcium receptor (CaR) in bone cells; the influence of simulated uraemia on the release of cytokines by bone cells; the factors mediating bone loss following renal transplantation and preventative strategies; the factors that control parathyroid function in vivo, including new vitamin D metabolites and calcimimetic agents; the pathogenesis of soft tissue calcification as it affects uraemic patients. Over the past few years his group has found that new structurally modified metabolites of vitamin D differ substantially in the way they influence the behaviour of both parathyroid cells and bone cells. His group has also devised, conducted and published studies of the first effective prophylaxis against bone loss in the post transplant setting and has contributed to the understanding of the roles of calcimimetics and new vitamin D analogues as treatments for uraemic hyperparathyroidism. John Cunningham frequently lectures nationally and internationally,
as well as serving on numerous international expert panels and working
groups. Ove FurnesChairman Department of Orthopaedic Surgery His PhD thesis titled: "Hip and knee replacement in Norway 1987-2000. The Norwegian Arthroplasty Register", was a register based epidemiology study on knee and hip replacement. He is a consultant orthopaedic surgeon with a special interest
in prostheses surgery in rheumatic patients. Most of his scientific work
has been on register based observational studies in hip and knee replacement,
working with the ongoing prospective study on joint replacement in Norway
from 1987 until today. From 2002 he has been the Director of the Norwegian
Arthroplasty Register and from 2006 he became Chairman of the Department
of Orthopaedic Surgery at Haukeland Univsersity Hospital in Bergen. Mark Gurnell Dr Gurnell graduated from St Bartholomew’s Hospital
London, and it is here that he first developed his interest in endocrinology
under the combined tutelage of Professors GM Besser, JAH Wass & AB
Grossman. His interest in the molecular basis of endocrine disorders subsequently
took him to Cambridge (St John’s College), as a Wellcome Clinical
Training Fellow under the supervision of Professor VK Chatterjee, where
he undertook a PhD investigating the roles of the human thyroid hormone
b receptor and the peroxisome-proliferator-activated
receptor b in human disease. Having
completed his clinical training in Cambridge, he was appointed to a University
Lectureship in 2004 and now co-directs a research group, with Professor
Chatterjee, exploring the roles of nuclear receptors in human endocrine/metabolic
disease. In 2000 he was the recipient of the Medical Research Society’s
Young Investigator Gold Medal, and in 2001 the Society for Endocrinology’s
Young Clinical Endocrinologist of the Year award. Stephen HillStephen Hill is Professor of Molecular Pharmacology and Director of the Institute of Cell Signalling at the University of Nottingham in the UK. He is also Director and Founder of the company CellAura Technologies Ltd. Dr Hill studied at the University of Bristol and gained his PhD at the Department of Pharmacology, University of Cambridge in 1979. His current research interests include:
Michael HolickMichael F Holick, PhD, MD, is professor of medicine, physiology and biophysics and director of the General Clinical Research Center at Boston University Medical Center He has made numerous contributions to the field of the
biochemistry, physiology, metabolism, and photobiology of vitamin D for
human nutrition. He identified 25-hydroxyvitamin D from human blood, and
was the first to help structurally identify and chemically synthesize
1,25-dihydroxyvitamin D3. He determined the mechanism for how vitamin
D is synthesized in the skin, demonstrated the effect of aging, obesity,
latitude, seasonal change, sunscreen use, skin pigmentation, and clothing
on this vital cutaneous process, and established global recommendations
for exposure to sunlight as a major source of vitamin D. He has helped
increase awareness of the pediatric and medical community regarding the
extent that vitamin D deficiency exist in the US population, and its role
in causing metabolic bone disease, and osteoporosis in adults. Martin Hrabé de AngelisMartin Hrabé de Angelis studied biology at the Philipps University in Marburg and received his PhD in 1994. He worked as postdoctoral fellow from 94- 97 at the Jackson Laboratory in Bar Harbor/USA studying the Delta/Notch pathway and mouse mutant lines with impaired somitogenesis. He started his own research group in 97 at the GSF National Research Centre in Munich. In 2000 he was recruited as director of the Institute of Experimental Genetics at the GSF. Hrabe de Angelis is full professor at the Technical University in Munich and holds the chair of Experimental Genetics. At the same time he serves as director of the European Mouse Mutant Archive in Monterotondo/Rome Italy. His research focus is on large-scale mutagenesis, functional genomics using mouse models for the understanding of inherited diseases in man, the Delta/Notch pathway and bone related diseases. In 2002 he founded the German Mouse Clinic (GMC) for comprehensive phenotyping of mouse models. Markus KettelerDr Markus Ketteler is Consultant Nephrologist at the Department
of Nephrology and Clinical Immunology, University Hospital of the RWTH
Aachen, Germany, responsible for the Haemodialysis and the Renal Transplantation
Unit. Before this, Dr Ketteler had worked in the Department of Nephrology
at the University Hospital Benjamin Franklin, Free University, Berlin,
Germany (1989-1992 and 1994-2000), and in the Department of Nephrology
and Hypertension at the University Hospital in Salt Lake City, UT, USA
(1992-1994), where he had spending a 2-year Postdoctoral Fellowship working
on the role of nitric oxide in inflammatory glomerular diseases. His current
research focus is aimed at the understanding of pathomechanisms involved
in extra-osseous calcifications and cardiovascular disease in patients
with chronic kidney disease (CKD). His research group identified the deficiency
of fetuin-A, a circulating calcification inhibitor, as a uraemia- and
inflammation-related risk predictor of cardiovascular and all-cause mortality
in patients on dialysis. Irina KratchmarovaCurrent position (since 2005): Associate Professor at the Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark Education and Professional Experience: MSc in Molecular Biology, specialization: Animal and Human Physiology, Faculty of Biology, Sofia University, Sofia, Bulgaria, 1991-1997, (supervisor Professor Ignat Minkov); PhD from Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark, 1997-2001, (supervisor Professor Karsten Kristiansen); Assistant Professor in the group of Professor Matthias Mann, Center for Experimental Bioinformatics, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark, 2001-2005. Main Research Areas: Cell differentiation, quantitative
proteomics, signaling cascades, secreted molecules Beata Lecka-CzernikBeata Lecka-Czernik is an Associate Professor in the Department
of Geriatrics at the University of Arkansas for Medical Sciences, USA.
She obtained her undergraduate degree from the Warsaw University and his
PhD from the Institute of Biochemistry and Biophysics Polish Academy of
Sciences, both in Warsaw, Poland. She received her postdoctoral training
at the University of Arkansas for Medical Sciences and became UAMS faculty
in 1995. She has initiated research on the role of nuclear receptor PPARgamma
in the maintenance of adult bone mass by demonstrating that PPARgamma
plays a key regulatory role in the process of marrow mesenchymal stem
cells (MSCs) commitment toward osteoblasts and adipocytes. Dr. Lecka-Czernik’s
research interests include: 1) effects of aging and PPARgamma on differentiation
potential of MSCs; 2) effects of highly specific PPARgamma agonists and
anti-diabetic drugs, thiazolidinediones, on bone. She is the Editor for
the PPAR Research inaugural issue, PPARs and Bone Metabolism. Her research
has been supported by grants from the National Institute of Health and
the American Diabetes Association. Claes LindbergPhD in Organic Pharmaceutical Chemistry, Uppsala University,
Sweden (1978). Joined Astra Draco in Lund, Sweden, 1979 as team leader and associate director responsible for bioanalytical mass spectrometry. Currently holds a position as Associate Principal Scientist at Translational Sciences within AstraZeneca R&D in Lund. The research interest is focused on mass spectrometry applied to proteomics with special emphasis on biomarker discovery by combined chromatographic and mass spectrometric techniques.~ Matthias MannMatthias Mann (born 1959) is a scientist in the area of mass spectrometry and proteomics. Born 1959 in Germany he studied mathematics and physics at the University of Goettingen. He received his Ph.D. in 1988 at Yale University were he worked in the group of the later Nobel laureate John Fenn. After a postdoctoral fellowship at the University of Southern Denmark in Odense he became group leader at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Later he went back to Odense as a Professor for Bioinformatics. Since 2005 he is a director at the Max Planck Institute of Biochemistry in Munich. Michael McClungDr Michael McClung received his medical degree from the
University of Texas Southwestern Medical School in Dallas and completed
his residency at Parkland Memorial Hospital in the same city. His fellowship
in endocrinology was completed at the National Institutes of Health. He
is a Fellow of the American College of Physicians and the American College
of Endocrinology. He has served on the Board of the International Society
for Clinical Densitometry and the Committee of Scientific Advisors for
the International Osteoporosis Foundation. As Founding Director of the
Oregon Osteoporosis Center in Portland, Oregon and Assistant Director
of the Department of medical Education at Providence Portland Medical
Center, he is involved in medical education and clinical practice. His
Center has participated in the conduct of and reporting of many clinical
trials. Klaus OlgaardKlaus Olgaard is Professor of Nephrology and Internal Medicine at the University of Copenhagen and at Department of Nephrology, Rigshospitalet, Copenhagen, Denmark. His scientific interests are basic and clinical research in nephrology-endocrinology, especially related to calcium, phosphorus, parathyroid hormone (PTH), PTH related peptide, vitamin D, renal osteodystrophy and post-transplant bone disease. Professor Olgaard was the President for the ERA-EDTA congress held in Copenhagen in 2002. He is Past President of several national nephrology and transplantation societies including the Danish Society of Nephrology. He is subject editor for Nephrology Dialysis Transplantation, and has been a member of several editorial boards. Professor Olgaard has authored more than 200 publications
in peer-reviewed international journals and is the editor of the K/DIGO
guidelines, 2006 on: Bone and Mineral Metabolism in CKD. Eric OrwollDr Orwoll completed his undergraduate degree at the University of Michigan, received his MD from the University of Maryland School of Medicine and completed his residency in internal medicine at Providence Medical Center. A fellowship in Endocrinology and Metabolism was completed at the Oregon Health Sciences University in Portland. His appointments at the Oregon Health & Science University are numerous. Dr Orwoll is an Attending Physician, Director, Bone and Mineral Clinic and Densitometry Services; Director, Bone and Mineral Research Unit; Head, Bone and Mineral Section of the Division of Endocrinology, Diabetes, Clinical Nutrition; Professor of Medicine; Director, Clinical and Translational Sciences Institute; Associate Dean for Research in the School of Medicine and OHSU Associate Vice President for Research. Dr Orwoll’s major research interests include the epidemiology, etiology and therapy of osteoporosis, the effects of sex steroids on skeletal biology and skeletal genetics. He is the principal investigator on several research grants funded by the National Institutes of Health, including Osteoporotic Fractures in Men (MrOS), and is the author of over 150 peer reviewed publications, reviews, book chapters, and books. He is assigned to several National Committees. For instance, Dr Orwoll is a member of the Board of Trustees, National Osteoporosis Foundation and has been a member of the Orthopedics Study Section, NIH. He is a member of a variety of professional societies, including the American Society for Bone and Mineral Research, Endocrine Society, American Society for Clinical Nutrition and the Federation of American Societies for Experimental Biology. His editorial posts have included membership on the editorial
boards of the Journal of Bone and Mineral Research, the Journal
of Clinical Endocrinology and Metabolism, Endocrinology
and Clinical Densitometry. Dr Orwoll is a reviewer for many journals,
including Endocrinology, Bone, Osteoporosis International,
Journal of Clinical Investigation, JAMA, New England
Journal of Medicine and Annals of Internal Medicine. Stuart RalstonStuart Ralston graduated in medicine from Glasgow University in 1978 and developed an interest in metabolic bone disease during postgraduate training with Dr Iain T Boyle at Glasgow Royal Infirmary. Professor Ralston trained in general internal medicine and rheumatology in Glasgow between 1981 and 1988. He was appointed as a Wellcome Senior Clinical Research Fellow and Honorary Consultant at the University of Edinburgh between 1988 and 1990 and moved to Aberdeen to take up an appointment as Senior Lecturer in Medicine in 1991. He was appointed as Professor of Medicine and Bone Metabolism in 1996 and was Director of the Institute of Medical Sciences at Aberdeen between 2002 and 2004. Professor Ralston took up the ARC chair of Rheumatology at the University of Edinburgh in February 2005 and was appointed as Head of the School of Molecular and Clinical Medicine in November 2005. He is an Honorary Consultant Rheumatologist with Lothian Health Board and is lead clinician for Osteoporosis services within NHS Lothian. Professor Ralston has published extensively on several aspects of bone disease including the genetics of osteoporosis; the pathogenesis and management of Paget's disease of bone; the role of Nitric Oxide in bone and the pathogenesis and management of cancer-associated bone disease. He was President of the European Calcified Tissues Society between 1998 and 2005. He is currently joint editor-in-chief of Calcified Tissue International, associate editor of Bone; associate editor of Endocrinology and a member of the Editorial Board of the Journal for Bone and Mineral Research Frank RauchCurrent Position (since 2001): Assistant Director of Clinical Research at the Shriners Hospital for Children and Assistant Professor at the Department of Pediatrics of McGill University, Montreal, Canada. Education: MD from Munich Technical University, Germany, in 1991; pediatric training at the Children’s Hospital of Cologne University, Germany, 1991-1997 (supervisor Dr. E. Schoenau); research fellowship in bone development at the Shriners Hospital for Children, Montreal, 1997-1999 (supervisors Dr. R. St-Arnaud and Dr F. H. Glorieux). Scientific Activity: 105 peer-reviewed publications, 22 book chapters and proceedings contributions. Main Research Areas: Pediatric bone histomorphometry, musculoskeletal interaction, osteogenesis imperfecta Editorial Activity: Associate Editor, Journal
of Musculoskeletal and Neuronal Interactions; Editorial Board, Osteoporosis
International Jonathan ReeveJonathan trained at the MRC Clinical Research Centre and
the Endocrine Unit Massachusetts General Hospital. His early research
interests included the first clinical studies of PTH1-34 in osteoporosis
and new techniques in tracer studies and systems biology. His interest
in osteocytes was stimulated by a long-standing collaboration with Pierre
J Meurnier and Monique Arlot, which led to the first studies of osteocytes
apoptosis in sudden estrogen withdrawal with Brendon Noble and Nigel Loveridge.
He has also co-ordinated the European Prospective Osteoporosis Study,
with over 35 collaborating principal investigators and more than 100 scientific
papers including a series of meta-analysis, that give hope for better
identification of the patient at risk. His current interests include the
genetic epidemiology of osteoportic fractures (as a Principal Investigator
in the GENOMOS Consortium) and the regulation of bone formation and resorption
by osteocytic signalling in collaboration with colleagues at the Department
of Endocrinology in Leiden. Jonathan is currently a Director of Research
in the University Department of Medicine at Cambridge. Ruth RossDr Ruth Ross is a senior lecturer in Pharmacology at The University of Aberdeen in Scotland. Her primary research focus is cannabinoid receptor pharmacology and the pharmacology of the endocannabinoids and related metabolites. This research is directed towards discovery of the role of the endocannabinoids in pain, inflammation, obesity and bone disorders and the development of small molecules, which modulate the various elements of the endocannabinoid system as novel therapeutics. Kjeld SøballeProfessor, DMSc Expertise: A Francis StewartFrancis Stewart received his PhD from the University of New South Wales, Sydney Australia in 1986 for studies on the molecular biology of lactation. He then pursued post-doctoral work with Guenther Schuetz at the German Cancer Research Centre on chromatin and steroid hormone action. In 1991 he became a Group Leader in the Gene Expression Program at EMBL, Heidelberg where he combined work on chromatin and epigenetic mechanisms with the development of advanced genome engineering strategies for the mouse and other living systems. These include the now popular ligand (usually tamoxifen) regulated gene switch based on site specific recombination by Cre-steroid hormone receptor fusion proteins; the development of efficient FLP recombination by application of molecular evolution to obtain FLPe; and recombineering the use of homologous recombination by the lambda phage Red operon in E.coli for DNA engineering, particularly for engineering BACs (bacterial artificial chromosomes) and construction of complex targeting vectors. Recent studies of epigenetic mechanisms in chromatin have focused on histone lysine methylation and trithorax-Group action. Dr. Stewart became the founding Professor for Genomics
at the Dresden University of Technology in 2001. J Mark WilkinsonMark Wilkinson is a clinical fellow in hip arthroplasty
at The University of Sheffield, UK His research interests include the
pathogenesis and treatment of aseptic loosening after total hip arthroplasty,
for which he has received grant support from the Arthritis Research Campaign,
Royal College of Surgeons of England, and the John Charnley Trust. Previously
he was the International Arthroplasty Fellow at Wrightington Hospital,
Wigan, and a doctoral student with Professor Richard Eastell at The University
of Sheffield. He has been awarded the British Orthopaedic Association
Robert Jones Gold Medal and Association Prize, the British Hip Society
McKee Prize, National Osteoporosis Society Young Investigator Award, and
an Orthopaedic Research Society New Investigator Recognition Award. Klaus WilleckeKlaus Willecke, Professor of Genetics at the University of Bonn, Germany, since 1968. Ph.D. in Biochemistry at the University of Munich 1968, Postdoctoral work at Princeton University (USA) 1968-1971, Habilitation in Genetics at the University of Cologne 1973. Associate Professor of Cell Biology at the University of Essen (Medical School) 1977-1986, Sabbatical terms at Yale University, USA, 1973, Stanford University, USA, (1982), Massachusetts Institute of Technology, USA, (1993), and University of Munich (1999). Current research area: Biological functions of connexin
genes, transgenic mice, molecular biology. Mone ZaidiProfessor Mone Zaidi is Professor of Medicine, Geriatrics, and Physiology and Biophysics at The Mount Sinai School of Medicine in New York as well as the Director of The Mount Sinai Bone Program. Professor Zaidi has published over 200 articles including chapters and papers in journals such as Cell, Nature Cell Biology, Journal of Cell Biology, and Journal of Clinical Investigation. His research focuses on the developmental biology of bone and molecular and cellular mechanisms of skeletal remodeling during adult life. Dr Zaidi has been funded continuously initially by the Medical Research Council (MRC) and Arthritis Research Council in England, and thereafter, in the United States by the National Institutes of Health (NIH) and the Department of Veterans Affairs. Professor Zaidi was elected to the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), the Oslerian Interurban Clinical Club and the Society of Osteobiology. He served as Chair of the Orthopedics and Musculoskeletal Grant Review Committee of the NIH, and for two separate terms, as Chair of the VA’s Endocrine Grant Review Panel. He was admitted to Fellowship of the Royal College of Physicians of London and Dublin, Royal College of Pathologists of London, American College of Endocrinology, American College of Physicians, and Institute of Biologists (London). Dr Zaidi has been invited internationally to give lectures,
and was recently “Invited Speaker” at the Japanese Society
for Bone and Mineral Research.
|
||||||||||||||||
|
|
||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
